Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus SOMA.
CHLORZOXAZONE vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."